- Home
- FBRX vs PRLD Comparison
FBRX vs PRLD Comparison
Compare FBRX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- PRLD
- Stock Information
- Founded
- FBRX N/A
- PRLD 2016
- Country
- FBRX United States
- PRLD United States
- Employees
- FBRX N/A
- PRLD N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- FBRX Health Care
- PRLD Health Care
- Exchange
- FBRX Nasdaq
- PRLD Nasdaq
- Market Cap
- FBRX 44.8M
- PRLD 50.1M
- IPO Year
- FBRX N/A
- PRLD 2020
- Fundamental
- Price
- FBRX $10.05
- PRLD $0.95
- Analyst Decision
- FBRX Strong Buy
- PRLD Strong Buy
- Analyst Count
- FBRX 3
- PRLD 2
- Target Price
- FBRX $80.50
- PRLD $4.50
- AVG Volume (30 Days)
- FBRX 67.3K
- PRLD 147.1K
- Earning Date
- FBRX 05-15-2025
- PRLD 05-06-2025
- Dividend Yield
- FBRX N/A
- PRLD N/A
- EPS Growth
- FBRX N/A
- PRLD N/A
- EPS
- FBRX N/A
- PRLD N/A
- Revenue
- FBRX N/A
- PRLD $7,000,000.00
- Revenue This Year
- FBRX N/A
- PRLD N/A
- Revenue Next Year
- FBRX N/A
- PRLD N/A
- P/E Ratio
- FBRX N/A
- PRLD N/A
- Revenue Growth
- FBRX N/A
- PRLD N/A
- 52 Week Low
- FBRX $4.11
- PRLD $0.61
- 52 Week High
- FBRX $28.68
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- FBRX 63.47
- PRLD 56.10
- Support Level
- FBRX $7.78
- PRLD $0.86
- Resistance Level
- FBRX $13.84
- PRLD $1.00
- Average True Range (ATR)
- FBRX 1.38
- PRLD 0.09
- MACD
- FBRX 0.20
- PRLD 0.00
- Stochastic Oscillator
- FBRX 50.44
- PRLD 73.78
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.